F10 and Stroke: Factor Xa (FXa) inhibitors are well-established in the treatment and prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) and are recommended as first-line anticoagulants for the prophylaxis of thromboembolic events in current guidelines [10, 14, 20, 39, 40].